Major depressive disorder (MDD) and treatment-resistant depression (TRD) affect a large global population. Standard SSRIs fail in 30–50% of patients and require weeks for clinical benefit. This delay has shifted attention to rapid-acting glutamatergic therapies.
Nitrous oxide (N₂O) acts as a non-competitive NMDA receptor antagonist. It blocks glutamate-mediated ion influx, restoring excitatory–inhibitory balance. It also reduces hyperconnectivity in the default mode network linked to rumination and modulates opioid and dopaminergic pathways that regulate mood and motivation.
Immediate Antidepressant Effects
A systematic review of seven clinical trials (n = 247) confirmed rapid antidepressant action. In studies using 50% N₂O:
- Significant symptom reduction occurred within 2 hours
- Effect persisted at 24 hours
- Pooled mean difference: −3.32 vs placebo
- In TRD patients, 15% remission in N₂O group vs 0% placebo
These results show that N₂O effectively bypasses the therapeutic delay of standard antidepressants.
Duration of Effect and Dosing
Single-session effects are short-lived. Meta-analysis shows:
- Strong response at 2 and 24 hours
- No sustained benefit at 1 week without repeat dosing
Repeated dosing (twice weekly for 4 weeks):
- Produces durable remission
- Remission rates up to 75%
Dose-response data show:
- 25% N₂O is effective with better tolerability
- 50% N₂O gives greater symptom reduction but higher side effects
Optimized maintenance schedules are required for sustained benefit.
Safety Profile
Adverse events were mild, transient, and self-limiting. No serious adverse events were reported. Side effects were dose-dependent.
| Adverse Event | 25% N₂O | 50% N₂O | Outcome |
|---|---|---|---|
| Nausea/Vomiting | Low | High | Higher at 50% |
| Dizziness | Mild | Frequent | Both > placebo |
| Headache | Minimal | Increased | Higher at 50% |
Interpretation:
25% N₂O offers better tolerability for maintenance; 50% offers higher acute efficacy.
Critical Limitations
- Small sample sizes
- Early-phase trial designs
- Blinding bias due to psychoactive effects
- Short duration compared to ketamine (which lasts ~7 days)
However, N₂O causes fewer dissociative and cardiovascular effects than ketamine.
Nitrous oxide is a validated rapid-acting antidepressant with effects occurring within 2–24 hours, making it clinically valuable for acute symptom control in MDD and TRD. However, single-dose effects are transient, and long-term use requires repeated dosing protocols. Large-scale trials are still required to confirm long-term safety and maintenance strategies.
